$68.37
3.45% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$68.37
+3.02 4.62% 1M
-0.86 1.24% 6M
-0.70 1.01% YTD
+7.02 11.44% 1Y
-8.99 11.62% 3Y
-34.11 33.28% 5Y
-32.45 32.19% 10Y
+61.27 862.96% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-2.44 3.45%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Basic
Market capitalization
$13.2b
Enterprise Value
$10.9b
Net debt
$-2.4b
Cash
$2.4b
Shares outstanding
193.8m
Valuation (TTM | estimate)
P/E
683.70 | 11.56
P/S
3.00 | 2.75
EV/Sales
2.46 | 2.26
EV/FCF
35.89
P/B
3.61
Financial Health
Equity Ratio
63.33%
Return on Equity
0.95%
ROCE
5.91%
ROIC
2.26%
Debt/Equity
0.01
Financials (TTM | estimate)
Revenue
$4.4b | $4.8b
EBITDA
$261.9m | $1.5b
EBIT
$238.0m
Net Income
$21.3m | $1.1b
Free Cash Flow
$302.7m
Growth (TTM | estimate)
Revenue
17.13% | 13.48%
EBITDA
-64.39% | 1,027.62%
EBIT
-66.60%
Net Income
-97.15% | 3,413.92%
Free Cash Flow
-61.72%
Margin (TTM | estimate)
Gross
93.19%
EBITDA
5.93% | 31.69%
EBIT
5.39%
Net
0.48% | 23.82%
Free Cash Flow
6.86%
More
EPS
$0.10
FCF per Share
$1.56
Short interest
5.99%
Employees
2.62k
Rev per Employee
$1.62m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Incyte forecast:

16x Buy
48%
16x Hold
48%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Incyte forecast:

Buy
48%
Hold
48%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,413 4,413
17% 17%
100%
- Direct Costs 300 300
27% 27%
7%
4,113 4,113
16% 16%
93%
- Selling and Administrative Expenses 1,247 1,247
9% 9%
28%
- Research and Development Expense 2,604 2,604
58% 58%
59%
262 262
64% 64%
6%
- Depreciation and Amortization 24 24
5% 5%
1%
EBIT (Operating Income) EBIT 238 238
67% 67%
5%
Net Profit 21 21
97% 97%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Positive
Investors Business Daily
2 days ago
Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.
Neutral
Business Wire
2 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire.
Negative
Market Watch
8 days ago
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today